Search
Tovinontrine
go.drugbank.com/drugs/DB16193InvestigationalTovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease). … Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
PV903
go.drugbank.com/drugs/DB05163ExperimentalPV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
SPP1148
go.drugbank.com/drugs/DB05203ExperimentalSPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.
GSK-945237
go.drugbank.com/drugs/DB15345Investigationaland Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). … GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose
Aluminum zirconium trichlorohydrex gly
go.drugbank.com/drugs/DB11116ApprovedWithdrawnThe compound forms a colloidal plug in sweat pores, preventing sweat from leaving the body. … Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.
Dihydromorphine
go.drugbank.com/drugs/DB01565ExperimentalIllicitA semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. [PubChem]
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
MLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).